Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
6.98
+0.49 (7.55%)
At close: Apr 24, 2026, 4:00 PM EDT
6.74
-0.24 (-3.44%)
After-hours: Apr 24, 2026, 7:26 PM EDT
Verrica Pharmaceuticals Revenue
In the year 2025, Verrica Pharmaceuticals had annual revenue of $35.58M with 370.22% growth. Verrica Pharmaceuticals had revenue of $5.09M in the quarter ending December 31, 2025, with 1,380.23% growth.
Revenue (ttm)
$35.58M
Revenue Growth
+370.22%
P/S Ratio
3.37
Revenue / Employee
$468,118
Employees
76
Market Cap
119.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.58M | 28.01M | 370.22% |
| Dec 31, 2024 | 7.57M | 2.44M | 47.66% |
| Dec 31, 2023 | 5.12M | -3.91M | -43.27% |
| Dec 31, 2022 | 9.03M | -2.97M | -24.73% |
| Dec 31, 2021 | 12.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pyxis Oncology | 13.86M |
| Innate Pharma | 10.57M |
| Cibus | 3.64M |
| Cardiff Oncology | 593.00K |
| NeOnc Technologies Holdings | 39.99K |
VRCA News
- 16 days ago - Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting - GlobeNewsWire
- 19 days ago - Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - Business Wire
- 5 weeks ago - VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - Business Wire
- 5 weeks ago - Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - Business Wire
- 6 weeks ago - Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire